secwatch.observer — SEC 8-K summary
======================================

Issuer:     Elicio Therapeutics, Inc. (ELTX)
CIK:        0001601485
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001601485-24-000042
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elicio Q2 net loss $7.2M; Phase 1 data show 100% T cell response; Phase 2 enrollment Q4
--------------------------------------------------------------------------------

- Net loss of $7.2M ($0.64 per share) for Q2 2024; cash $3.4M at June 30, but subsequent financings raised ~$29.6M net.
- AMPLIFY-7P Phase 1 data: 100% of patients developed mKRAS-specific T-cell response; median DFS not reached at RP2D (4.9mg).
- Phase 2 randomized trial enrollment expected to complete Q4 2024; interim analysis anticipated Q1 2025.
- AMPLIFY-201 long-term follow-up to be terminated; updated data at upcoming medical meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/0001601485-24-000042-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601485/000160148524000042/angn-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001601485-24-000042

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer